1. Introduction {#sec1}
===============

Pancreatic cancer is one of the most lethal malignancies, with a 5-year survival rate of only 4-5% \[[@B1]\]. The major reasons for the poor prognosis may be late diagnosis and limited therapeutic options; early diagnosis of pancreatic cancer is a pressing clinical problem.

Serum levels of the conventional tumor markers including carcinoembryonic antigen (CEA) and the Lewis blood group carbohydrate antigen (CA19-9) often remain in normal range at early stages of this malignancy \[[@B2]\]. Therefore, search for novel biomarkers of pancreatic cancer is needed.

Recent advances in proteomic technologies have provided promising ways to discover and identify novel biomarkers in various fields of clinical medicine. Although there has been long and uncertain path from marker discovery to clinical utility \[[@B3]\], sophisticated technologies have facilitated the discovery of potential tumor markers with improved sensitivities and specificities for the diagnosis of cancer patients \[[@B4]\]. Also, proteome analysis can lead to biomarkers that may be useful in the prediction of clinical response to anticancer therapy \[[@B5]\].

Surface enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) is a representative example of a proteomics technique for the high-throughput fingerprinting of serum proteins and peptides and biomarker discovery \[[@B6]\]. Using this technology, we could detect and identify novel diagnostic markers for alcohol abuse \[[@B7]\] and also a new prognostic marker for pancreatic cancer \[[@B8]\].

One of the technical challenges in serum proteome analysis is that serum contains thousands of proteins and peptides that are present in a large dynamic concentration \[[@B9]\]. Indeed, 22 abundant proteins such as albumin, immunoglobulins, and transferring constitute up to 99% of the protein content of plasma \[[@B10]\]. In proteomic studies searching for low-abundance serum proteins or peptides, depletion of those abundant proteins and further fractionation of samples will be necessary.

We recently conducted a three-step proteome analysis involving removal of 12 abundant proteins and subsequent reversed-phase high-performance liquid chromatography fractionation and one-dimensional electrophoresis: we successfully identified three proteins including YKL-50 as a promising biomarker of sepsis \[[@B11]\].

Proteomics in pancreatic cancer research including serum or plasma biomarker search has been reviewed \[[@B12]\]. A three-step approach as-we used in this study has not been tried in biomarker search for pancreatic cancers before.

In this study, we applied this three-step proteome analysis to find novel biomarkers of pancreatic cancer.

2. Method {#sec2}
=========

2.1. Patients Studied {#sec2.1}
---------------------

Serum samples were obtained preoperatively from a total of 32 patients diagnosed with primary invasive pancreatic ductal carcinoma who had surgery at the Department of General Surgery, Chiba University Hospital. Clinical data of 32 patients are summarized in [Table 1(a)](#tab1){ref-type="table"}. Serum samples were also obtained from apparently healthy and age-matched subjects who had medical checkup at the Port-square Kashiwado Clinic, Kashiwado Memorial Foundation ([Table 1(b)](#tab1){ref-type="table"}). All samples were frozen by liquid nitrogen and were stored at −80°C until analysis. Written informed consent was obtained from all the subjects. The ethics committee of our institute approved the protocol.

2.2. A Three-Step Serum Proteome Analysis {#sec2.2}
-----------------------------------------

### 2.2.1. Immunoaffinity Subtraction of Highly Abundant Proteins from Human Serum {#sec2.2.1}

Serum samples obtained from 4 patients with pancreatic cancer (Nos 1\~4 in [Table 1(a)](#tab1){ref-type="table"}) were pooled. Sera obtained from 4 age-matched healthy volunteers were also pooled (Nos 1\~4 in [Table 1(b)](#tab1){ref-type="table"}). As the first step of proteome analysis, the twelve most abundant proteins (albumin, Immunoglobulin G, transferrin, fibrinogen, Immunoglobulin A, Immunoglobulin M, apolipoprotein A-I, apolipoprotein A-II, haptoglobin, *α*1-acid glycoprotein and *α*2-macroglobulin) were removed from serum by passage through a commercially available immunoaffinity column, the ProteomeLab IgY12HC LC10 (Beckman coulter, Inc. Fullerton, CA. USA.) Ninety microliters of each pooled sample was subjected to the immunoaffinity subtraction as we previously described \[[@B11]\]. The combined flow-through fractions were concentrated by Vivaspin2 spin concentrators (molecular weight cutoff, 10 kDa, Vivascience, Hannover, Germany) and were stored at −80°C until use.

In addition, sera from 32 patients with pancreatic cancer and 32 healthy volunteers were used for validation. Eight healthy controls and 8 of relatively advanced cases (Nos 1\~8 in Tables [1](#tab1){ref-type="table"}(a) and [1](#tab1){ref-type="table"}(b)) were chosen for first validation and 24 of them (Nos 9\~32 in Tables [1](#tab1){ref-type="table"}(a) and [1](#tab1){ref-type="table"}(b)) were used for the second validation experiment.

2.3. HPLC Separation of Immunoaffinity-Subtracted Serum Samples {#sec2.3}
---------------------------------------------------------------

Immunoaffinity-subtracted serum samples prepared as described above were separated by reverse-phase HPLC in an automated HPLC system, the SHISEIDO Nanospace SI-2 (Shiseido Fine Chemicals, Tokyo, Japan) essentially as we described before \[[@B11]\]. A total of 40 fractions were collected at 0.5 min intervals from 19.6 to 39.6 min. Each fraction was immediately lyophilized by a centrifugal vacuum concentrator and stored at −80°C until further analysis.

2.4. Two-Dimensional Gel Electrophoresis {#sec2.4}
----------------------------------------

The IEF gels (70 mm length, Inner 2.5 mm diameter and pH ranges from 3 to 10) were prepared as previously described \[[@B13], [@B14]\]. The lyophilized samples (from fraction 6 to fraction 25) were dissolved with 15 *μ*L sample preparation buffer and proteins were separated by two-dimensional gel electrophoresis with agarose gels in the first dimension as described by Oh-Ishi et al. \[[@B13]\].

2.5. In-Gel Digestion and LC-MS/MS {#sec2.5}
----------------------------------

CBB stained 2-DE images of pooled serum samples obtained from patients with pancreatic cancer were compared with those obtained from healthy volunteers. Differentially expressed protein bands were excised from the gel and were subjected to in-gel tryptic digestion as previously reported \[[@B14]\]. Digested peptides were injected into a trap column: 0.3 × 5 mm L-trap column (Chemicals Evaluation and Research Institute, Saitama, Japan) and an analytical column: 0.1 × 50 mm Monolith column (AMR, Tokyo, Japan), which was attached to a HPLC system (Nanospace SI-2; Shiseido Fine Chemicals, Tokyo, Japan). The flow rate of a mobile phase was 1 *μ*L/min. The solvent composition of the mobile phase was programmed to change in 35 min cycles with varying mixing ratios of solvent A (2% v/v CH~3~CN and 0.1% v/v HCOOH) to solvent B (90% v/v CH~3~CN and 0.1% v/v HCOOH): 5--50% B 20 min, 50--95% B 1 min, 95% B 3 min, 95--5% B 1 min, 5% B 10 min. Purified peptides were introduced from HPLC to an LTQ-XL (Thermo Scientific, CA, USA), an ion trap mass spectrometer (ITMS), via an attached Pico Tip (New Objective, MA, USA). The MS and MS/MS peptide spectra were measured in a data-dependent manner according to the manufacturer\'s operating specifications. The Mascot search engine (Matrixscience, London, UK) was used to identify proteins from the mass and tandem mass spectra of peptides. Peptide mass data were matched by searching the Human International Protein Index database (IPI, July 2008, 72079 entries, European Bioinformatics Institute) using the MASCOT engine. The minimum criterion of the probability-based MASCOT/MOWSE score was set with 5% as the significant threshold level. When the candidates had SEQUEST scores lower than 100 or when the SEQEUST score was computed by using fewer than one peptides fragment, we inspected the raw MS and MS/MS spectra of peptides to judge their qualities (see Figures a--f in Supplementary Material available online at doi: 10.1155/2011/628787).

2.6. Western Blot Analysis {#sec2.6}
--------------------------

Western blotting was performed as we previously described \[[@B15]\].

Briefly, immunoaffinity-subtracted serum samples were separated on SDS-PAGE in 10--20% polyacrylamide gradient gel (DRC, Tokyo, Japan) and were transferred to polyvinylidene fluoride membranes (0.45 *μ*m thickness, Millipore, Bedford, MA) at 10 V for overnight. The following antibodies commercially available were used as primary antibodies; mouse anti-human ApoA-IV antibody (BML Inc., Tokyo, Japan), mouse anti-human GC antibody (LifeSpan, Inc., UK), mouse monoclonal anti-human RBP4 antibody (Abnova.Com., Taipei, Taiwan) and mouse anti-human CLEC3B antibody (BioPorto, Grusbakken 8, DK-2820 Gentofte, Denmark). Antigens on the membrane were detected with enhanced chemiluminescence detection reagents (GE Healthcare). Band intensities of the western blot images were quantified by TotalLab TL12 imaging analysis software (Shimadzu Co., Ltd. Kyoto, Japan) and were presented by arbitrary units.

2.7. Other Procedures {#sec2.7}
---------------------

In addition to western blotting, ELISA was conducted in some marker candidates using human ApoA-IV ELISA kit (Millipore, Missouri, USA), GC ELISA kit (immundiagnostik AG, Bensheim), and RBP4 ELISA kit; (R & D systems). Their optical density was measured at 450 nm using a microplate reader (iMark Microplate Reader S/N 10288). Serum levels of CEA and CA19-9 were determined by established commercially available kits.

2.8. Statistical Analysis {#sec2.8}
-------------------------

Statistical analysis was conducted using KaleidaGraph 4.0 J (Synergy Software, Reading, PA) and IBM SPSS Statistics 18 (SPSS Inc., IL, USA). Significance was defined as *P* \< 0.05.

3. Results {#sec3}
==========

3.1. Discovery and Identification of Differentially Expressed Proteins by a Three-Step Proteome Analysis {#sec3.1}
--------------------------------------------------------------------------------------------------------

To discover and identify novel serum markers for pancreatic cancer, we employed a comparative three-step proteome analysis of the pooled serum samples obtained from patients with pancreatic cancer and healthy volunteers. As the first step, 12 abundant proteins were removed by immunosubtractions. The immunoaffinity-subtracted samples were separated by RP-HPLC, and 20 fractions (fractions Nos 6--25) were subjected to 2-DE. A representative example is shown in [Figure 1](#fig1){ref-type="fig"}. By comparing the 2-DE images of the proteins included in the 20 fractions, a total 186 spots were found to be differently expressed. Subsequent LC-MS/MS could identify 100 proteins. Excluding keratins, complements and trypsin, 58 proteins were selected; 37 of them were upregulated and 21 were downregulated (Tables [2](#tab2){ref-type="table"}(a) and [2](#tab2){ref-type="table"}(b)).

3.2. Validation of Marker Candidates by Western Blotting {#sec3.2}
--------------------------------------------------------

Out of the 58 proteins listed in Tables [2](#tab2){ref-type="table"}(a) and [2](#tab2){ref-type="table"}(b), we focused on 19 proteins the alterations of which at serum level have not been studied in detail before, and also antibodies to be used for validation studies are available. Initial validation was conducted using 8 serum samples (nos. 1--8 in [Table 1](#tab1){ref-type="table"}) obtained from relatively advanced cases with pancreatic cancer including the four cases used for the three-step analysis. Western blotting of the 19 proteins indicated in Tables [2](#tab2){ref-type="table"}(a) and [2](#tab2){ref-type="table"}(b) revealed that expression of 7 proteins were found to be significantly decreased in patients with pancreatic cancers compared with controls: they were inter-alpha trypsin inhibitor heavy chain H1 (ITIH1), hemopexin precursor (HPX), alpha-1B-glycoprotein precursor (A1BG), apolipoprotein A-IV precursor (ApoA-IV), vitamin D-binding protein precursor (GC), plasma retinol-binding protein precursor (RBP4), and tetranectin (CLEC3B).

We then conducted the second validation study to test whether differential expression of the 7 protein candidates described above is reproducible using another set of serum samples obtained from 24 patients with pancreatic cancers including cases with relatively early stages (nos. 9--32 in [Table 1(a)](#tab1){ref-type="table"}). As shown in [Figure 2(a)](#fig2){ref-type="fig"} the expression levels of the four proteins ApoA-IV, GC, RBP4, and CLEC3B were greater in cancer patients than in controls. The differences were statistically significant assessed by densitometry [Figure 2(b)](#fig2){ref-type="fig"}.

3.3. Validation of Marker Candidates by ELISA {#sec3.3}
---------------------------------------------

ELISA kits were commercially available for GC, ApoA-IV, and RBP4. Their serum levels were determined in the 15 pairs of serum samples obtained from relatively early stages of patients used for the second validation by western blotting. Serum ApoA-IV levels of patients with pancreatic cancer (107.8 ± 99.9 AU) were significantly lower than those in healthy volunteers (195.2 ± 66.9 AU, *P* = 0.008) [Figure 3(a)](#fig3){ref-type="fig"}. GC levels were significantly lower in the patient group with pancreatic cancer (25.4 ± 10 UA) when compared with healthy group (34.3 ± 10.3 AU, *P* = 0.03) [Figure 3(b)](#fig3){ref-type="fig"}. Also, serum RBP levels in the patients (43.0 ± 5.9 AU) were significantly lower than in the controls (50.2 ± 4.2, *P* = 0.0004) [Figure 3(c)](#fig3){ref-type="fig"}.

3.4. Comparison of the Marker Candidates with CEA and CA19-9 {#sec3.4}
------------------------------------------------------------

[Figure 4](#fig4){ref-type="fig"} shows the receiver-operating characteristic curve (ROC) analysis for the three marker candidates determined by ELISA and those for CEA and CA19-9.The areas under the curves for ApoA-IV, GC, RBP4, CA19-9, and CEA were 0.79, 0.72, 0.85, 0.88, 0.58, 0.88, 0.89, and 0.89, respectively. Also, AUCs of the combination assay of GC/CA19-9, ApoA-IV/CA19-9, and RBP/CA19-9 were 0.88, 0.89, and 0.89, respectively.

In Tables [3](#tab3){ref-type="table"}(a) and [3](#tab3){ref-type="table"}(b), serum levels of ApoA-IV, GC and RBP4 determined by ELISA are listed together with CEA and CA19-9. There were 7 cases in which serum CA19-9 level was not elevated. Out of these 7 cases, ApoA-IV levels were below the lower reference interval value (mean SD) in 2 cases. Also, GC levels were below the lower reference interval value in one case.

4. Discussion {#sec4}
=============

The sequencing of the human genome has opened the door for comprehensive analysis of all the messenger RNA (transcriptome) and proteins (proteome). Messenger RNA concentrations, however, are not necessarily predictive of corresponding protein concentrations. Indeed, a recent report indicates that the sharing rate between cDNA microarray and proteome-based profilings is limited for the identification of candidate biomarkers in renal cell carcinoma \[[@B16]\]. Therefore, proteome analysis is one of the prerequisite for development of novel biomarkers. Proteomic studies in pancreatic cancers have been conducted by many research groups as reviewed \[[@B12], [@B17]\]. Hwang et al. found by using 2-DE/MS that phosphoglycerate kinase (PGK) 1, a secretable glycolytic enzyme involved in angiogenesis, is overexpressed in serum samples of pancreatic cancer patients, as compared to controls \[[@B18]\]. More recently, using the two-dimensional image-converted analysis of liquid chromatography and mass spectrometry (2DICAL) and a ''glyco capturing" through concanavalin A-agarose, Ono et al. identified a novel prolyl-hydroxylation of fibrinogen alpha chain in plasma samples obtained from patients with pancreatic cancers \[[@B19]\].

In this study, the three-step procedure was carried out to discover novel markers of pancreatic cancer. The outline of the three-step procedures is shown in [Figure 5](#fig5){ref-type="fig"}.

As a first step, serum samples were subjected to antibody-based immunoaffinity column that simultaneously removes 12 abundant serum proteins. The concentrated flow-through was then fractionated using reversed-phase HPLC. Proteins obtained in each HPLC fraction were further separated by 2-DE. A total of 58 differentially expressed proteins were identified. As results of initial validation by western blotting in relatively advanced cases and further validation including the less advanced cases by western blotting, the expression levels of the four proteins ApoA-IV, GC, RBP4, and CLEC3B were greater in cancer patients than in controls. Out of these four proteins, ELISA were available in apolipoprotein A-IV, retinol-binding protein precursor (RBP4), and vitamin D binding protein (GC). Serum levels of these 3 proteins were significantly lower in patients with pancreatic cancer than in healthy volunteers. In ROC analyses, the area under the curves for these three proteins was not significantly greater than that for CA19-9, but it is noteworthy that among the 4 cases of pancreatic cancers in which serum levels of both CEA and CA19-9 were within the reference intervals, at least one of ApoA-IV, RBP4, and GC was found to be decreased in 2 cases, suggesting that these candidate markers could be complementary to the conventional markers in diagnosis of pancreatic cancer.

ApoA-IV is present in human intestinal epithelial cells and is secreted as a chylomicron and VLDL apoprotein \[[@B20]\].

Retinol binding protein 4 (RBP4) is a 21-kDa protein synthesized in the liver and adipose tissue; its major function is to deliver retinol to tissue \[[@B21]\]. Fabris et al. determined serum RBP levels in patients with pancreatic cancer and found that the levels decreased concomitant with zinc and prealbumin levels \[[@B22]\]. Serum zinc levels were not significantly correlated with RBP4 levels in the present study (data not shown).

Vitamin D-binding protein is a plasma protein involved in vitamin D transport and other function. Although diagnostic role of this protein in pancreas cancer has not been reported yet, inhibitory role of vitamin D binding protein-macrophage activating factor (DBP-maf) in pancreatic carcinogenesis has been pointed out \[[@B23]\].

Tetranectin binds to kringle 4 of plasminogen, enhancing the plasminogen activation by tissue-type plasminogen activator in the presence of poly-D-lysine \[[@B24]\] Low serum levels of tetranectin (CLEC3B) are associated with increased risk of second-line chemoresistance in patients with ovarian cancer \[[@B25]\]. Also, in colorectal cancer, significantly shorter survival was found for patients with CLEC3B levels below a cut-off point of compared to patients with levels above \[[@B26]\].

Thus, the results of this study show that four serum proteins, apolipoprotein A-IV, vitamin D binding protein, retinol-binding protein 4, and tetranectin are significantly decreased in patients with pancreatic cancer. It was notable that these changes were observed in some patients in whom conventional tumor markers for this malignancy were not altered.

The reasons why serum levels of these proteins were decreased in pancreatic cancer patients are not clear at the moment. It is unlikely that the alterations were entirely due to malnutrition because serum levels of the 4 proteins were not significantly correlated with their serum albumin levels. It is possible that some negative mediators originated from tumor and/or the cancer-tissue microenvironments were regulating their production. It is unlikely that the alterations were due to biliary obstruction because the extent of the alterations of the four markers were not related to the extent of biliary obstruction (data not shown). Alterations of these four proteins in chronic pancreatitis as well as biliary tract diseases remain to be studied. Also, it remains to be determined whether serum levels of these four proteins are changed in other gastroenterological cancers.

Although exact mechanisms responsible for the reduction remain to be investigated, alterations of serum levels of apolipoprotein A-IV, vitamin D binding protein, tetranectin, and retinol binding protein may have complementary role in diagnosis of pancreas cancer.

Supplementary Material {#supplementary-material-sec}
======================

###### 

Supplemental Figures: Raw data of the proteins which had SEQUEST scores lower than 100 or when the SEQEUST score was computed by using fever than one peptides fragment. The horizontal axis is molecular weight of peptide and the y-axis is intensity. Figure a: Raw date of isoform 1 of flcolln-3-precursor. Figure b: corticosteroid-binding globulin precursor. Figure c: cholinesterase precursor. Figure d: AMBP protein precursor. Figure e: tetranectin precursor. Figure f: histone 4.

###### 

Click here for additional data file.
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![Comparison of 2-DE images of the same fraction of healthy volunteer control and pancreatic cancer patient sample. Electrophoresis was performed on the same gel and at the same condition. [Figure 1](#fig1){ref-type="fig"} is an example of Coomassie blue-stained gel displaying spots from depleted and fractionated serum from control (left, *n* = 4, pooled) and pancreatic cancer patients (right, *n* = 4, pooled). (Fraction number is 10th). Double circles indicate increased spot in pancreatic cancer. Single circle indicates decreased spot in pancreatic cancer.](IJPRO2011-628787.001){#fig1}

![(a) Magnified views of 2-D gel images and western blotting analysis of ApoA-IV, GC, plasma retinol binding protein 4 RBP4, and CLEC3B in serum samples. Coomassie blue-stained 2-D gel images from pooled control and pancreatic cancer displaying the protein spots for ApoA-IV, GC, RBP4, and CLEC3B are shown in left panels (a1), (a2), (a3) and (a4). Western blotting of these four proteins are shown in the right panel (b1), (b2), (b3) and (b4). (b) Quantitation of differentially expressed serum proteins in pancreatic cancer and healthy volunteers by Western blot analysis. Intensities of each band were calculated by TotalLab TL 120 software. Closed circles indicate healthy volunteers and closed squares indicate patients with pancreatic cancer. Significance of the differences were calculated by using Wilcoxon Mann-Whitney test. Panel A: ApoA-IV levels of serum were significantly lower in the depleted sera of pancreatic cancer when compared with the depleted sera of healthy volunteers (*P* \< 0.0001). Panel (B, C and D) are for proteins GC, RBP4, and CLEC3B and their serum levels were likewise lower in the pancreatic cancer patients. Their *P* values are lower than 0.0001, 0.001, and 0.009, respectively.](IJPRO2011-628787.002){#fig2}

![Quantitation of differentially expressed proteins in pancreatic cancer by ELISA. ELISA was performed using human ApoA-IV ELISA kit vitamin D binding protein ELISA kit and RBP4 ELISA kit, in serum samples obtained from 15 patients with pancreatic cancers and 15 control subjects. Analysis was performed by using Wilcoxon Mann-Whitney test. Closed circles indicate control and closed squares indicate cancer. (a): ApoA-IV levels of serum of patient with pancreatic cancer group (107.76 ± 25.8 AU) were lower than those in healthy group (185.27 ± 16.0 AU, *P* = 0.01); (b): GC levels were significantly lower in the patient group with pancreatic cancer (25.35 ± 9.8 UA) when compared with healthy group (34.40 ± 10.2 AU, *P* = 0.03); (c): RBP4 levels were lower in the pancreatic cancer group (42.99 ± 1.5 AU) than healthy group (50.7 ± 1.00 AU, *P* \< 0.001).](IJPRO2011-628787.003){#fig3}

![Receiver operating characteristic (ROC) curves for CA19-9, CEA, ApoA-IV, GC, RBP4 Their AUCs are described in the text.](IJPRO2011-628787.004){#fig4}

![Outline of the procedure for the three-step serum proteome analysis.](IJPRO2011-628787.005){#fig5}

###### 

\(a\) Clinical features of pancreatic cancer patients.

  No         Gender   Age (years)   UICC-stage   Tumor size (mm)   TP (g/dL)   ALB (g/dL)   Che (U/L)      T-Cho (mg/dL)
  ---------- -------- ------------- ------------ ----------------- ----------- ------------ -------------- ---------------
  1          M        66            III          35                6.7         4.3          270            220
  2          M        66            III          39                6.6         4.4          359            198
  3          M        79            IV           10                6.2         3.8          179            155
  4          M        71            III          18                6.8         4.0          207            210
  5          M        65            III          35                7.0         3.7          189            131
  6          M        78            III          50                6.6         4.4          359            198
  7          M        66            IIA          30                6.3         4.1          267            176
  8          M        62            IV           10                5.9         3.6          171            169
  9          M        38            IA           10                6.7         4.0          289            179
  10         M        50            IB           30                7.3         4.6          408            203
  11         M        63            IIA          18                6.6         3.9          260            138
  12         M        62            IIA          38                6.0         3.4          124            149
  13         M        54            IIA          24                7.0         4.5          198            162
  14         M        73            IIA          25                6.7         4.1          242            176
  15         F        76            IIA          26                5.0         3.3          162            95
  16         M        63            IIB          15                7.1         4.2          175            163
  17         M        65            IIB          32                5.8         3.5          227            113
  18         M        68            IIB          80                6.8         4.0          316            217
  19         M        71            IIB          24                7.5         4.1          221            144
  20         M        74            IIB          27                7.0         4.3          319            178
  21         F        68            IIB          27                6.5         4.0          223            177
  22         M        63            IIB          26                6.9         4.3          262            219
  23         F        68            IIB          27                6.1         3.5          339            163
  24         M        61            IIB          30                6.2         4.0          200            176
  25         F        74            IIB          40                6.6         3.8          221            170
  26         M        62            IIB          60                8.3         3.5          140            155
  27         F        73            IIB          35                5.9         3.2          130            169
  28         F        59            IIB          18                7.2         4.4          356            130
  29         M        73            IIB          50                5.7         3.3          127            135
  30         F        62            IIB          25                6.8         4.1          255            293
  31         F        71            III          25                6.8         4.2          294            159
  32         F        78            III          50                5.9         3.3          197            182
                                                                                                           
  Ave ± SD            66 ± 8.6                   30.9 ± 15.0       6.6 ± 0.6   3.9 ± 0.4    240.2 ± 75.6   171.9 ± 6.6

UICC: international union against cancer, M: male, F: female. TP: total protein. ALB: albumin. Che: cholinesterase. T-Cho: total cholesterol. Ave: average. SD: standard deviation.

From number 1 to 4 were used for 2-DE, from number 1 to 8 were for first western blot, from number 9 to 32 were for second western blot.

###### 

\(b\) Clinical features of healthy controls.

  No         Gender   Age (years)   TP (g/dL)   ALB (g/dL)   Che (U/L)    T-Cho (mg/dL)
  ---------- -------- ------------- ----------- ------------ ------------ ---------------
  1          M        62            7.5         4.7          401          203
  2          M        61            7.7         5.1          396          269
  3          M        64            7.2         4.4          284          229
  4          M        73            7.6         4.7          216          203
  5          M        57            8.3         5.0          430          301
  6          M        57            6.7         4.8          328          253
  7          M        65            7.2         4.8          375          230
  8          M        64            7.2         4.6          327          296
  9          M        55            6.9         4.6          300          211
  10         M        71            7.1         4.7          290          267
  11         F        64            8.1         5.4          293          192
  12         M        71            7.2         4.5          233          213
  13         M        55            7.2         4.5          365          227
  14         M        68            7.4         4.4          300          255
  15         F        67            7.0         4.5          279          172
  16         F        71            7.0         4.5          297          220
  17         M        60            6.7         4.2          284          183
  18         M        61            7.0         4.7          260          198
  19         M        55            6.4         3.9          304          176
  20         F        70            7.6         4.7          398          225
  21         M        70            7.3         4.6          257          250
  22         F        67            7.4         4.5          304          194
  23         M        60            7.0         4.4          338          234
  24         F        77            8.1         5.0          416          274
  25         F        62            7.5         4.6          284          169
  26         F        64            7.2         4.5          280          208
  27         M        65            7.4         4.6          264          231
  28         M        61            7.8         4.3          319          239
  29         M        61            7.3         4.6          309          271
  30         M        66            7.5         5.0          375          278
  31         F        65            7.6         4.5          339          288
  32         M        73            7.1         4.4          306          211
                                                                          
  Ave ± SD            64.4 ± 5.7    7.3 ± 0.4   4.6 ± 0.3    317 ± 53.4   230.3 ± 36.9

M: male, F: female. TP: total protein. ALB: albumin. Che: cholinesterase. T-Cho: total cholesterol. Ave: average. SD: standard deviation.

From number 1 to 4 were used for 2-0 E, from number 1 to 8 were for first western blot, from number 9 to 32 were for second western blot.

###### 

\(a\) Proteins upregulated in pancreatic cancer.

  Protein\'s name                                              Experimental   Theoretical   Score^(1)^   Queries   Validation
  ------------------------------------------------------------ -------------- ------------- ------------ --------- ------------
  Histidine-rich glycoprotein precursor                        80000          59541         150          3         WB^(3)^
  Plasminogen precursor                                        100000         90510         331          8         
  IGHM protein                                                 50000          52754         105          2         
  TF Serotransferrin precursor                                 75000          77000         601          14        WB
  Isoform LMW of Kininogen-1 precursor                         70000          47853         242          6         
  F2 Prothrombin precursor (Fragment)                          90000          69992         486          8         
  Alpha-1B-glycoprotein precursor                              43000          54239         590          8         WB
  Vitronectin precursor                                        62000          54271         581          8         WB
  Hepatocyte growth factor-like protein precursor              85000          80268         284          6         WB
  Plasma kallikrein precursor                                  90000          71323         246          8         
  Ceruloplasmin precursor                                      115000         122128        1452         49        
  Isoform 1 of Ficolin-3 precursor                             34400          32883         58           1         
  Transthyretin precursor                                      95000          15877         4489         13        
  Serum amyloid P-component precursor                          24000          25371         2293         12        
  Antithrombin III variant                                     61000          52658         1984         20        
  SERPINC1 protein                                             61000          29074         1147         11        
  Carbonic anhydrase 1                                         30800          28852         679          10        WB
  Isoform 1 of C-reactive protein precursor                    26000          25023         169          6         
  Apolipoprotein A-1                                           31600          30759         225          4         
  Isoform 1 of Inter-alpha-trypsin inhibitor heavy chain H3    138000         75031         529          12        
  Leucine-rich alpha-2-glycoprotein precursor                  47000          38154         549          8         
  Isoform 1 of N-acetylmuramoyl-L-alanine amidase precursor    68900          67957         193          4         
  Xaa-Pro dipeptidase                                          53700          54513         144          3         
  Inter-alpha (globulin) inhibitor H4                          130500         103261        1242         26        WB
  Vitamin K-dependent protein S precursor                      84000          75074         136          4         WB
  Serpin peptidase inhibitor, clade D (Heparin cofactor),      72000          57034         374          9         
  Isoform 1 of Fibronectin precursor                           200000         262442        553          14        WB
  Alpha-1-antichymotrypsin precursor                           62800          50566         3315         33        WB
  Kallistatin precursor                                        59600          48511         123          2         
  Plastin-2                                                    72000          70245         215          5         
  Corticosteroid-binding globulin precursor                    62500          45112         52           1         
  Myosin-1                                                     31600          222976        96           2         
  Isoform 1 of Serum albumin precursor                         73000          69321         261          9         
  Cholinesterase precursor                                     83000          72836         50           1         
  AMBP protein precursor                                       200000         38974         68           1         
  Plasma protease C1 inhibitor precursor                       87000          55119         1168         15        
  A[p]{.ul}oli[p]{.ul}o[p]{.ul}rotein B-100 [p]{.ul}recursor   300000         515241        3982         117       

^(1)^MOWSE score of candidate proteins.

^(2)^Number of peptide fragments yielding informative MS/MS.

^(3)^WB: western blot.

###### 

\(b\) Proteins downregulated in pancreatic cancer.

  -------------------------------------------------------- -------------- -------------- ------------ --------- ------------
  Protein\'s name                                          Experimental   Theoretical    Score^(1)^   Queries   Validation
  mass (Da)                                                mass (Da)      matched^(2)^                          
                                                                                                                
  Plasma retinol-binding protein precursor                 19000          22995          373          8         WB^(3)^
  Coagulation factor XII precursor                         75000          67774          140          5         
  Tetranectin precursor                                    19000          22552          61           1         WB
  Hyaluronan-binding protein 2 precursor                   68000          62630          195          6         
  Vitamin D-binding protein precursor                      55000          52883          284          14        WB
  Hemopexin precursor                                      75000          51643          635          8         WB
  Lumican precursor                                        100000         38405          120          6         WB
  Isoform 1 of Gelsolin precursor                          80000          85644          1360         23        WB
  Afamin precursor                                         80000          69024          307          7         
  Carboxypeptidase N catalytic chain precursor             49000          52253          244          12        WB
  Inter-alpha-trypsin inhibitor heavy chain H1 precursor   200000         101326         812          13        WB
  Histone H4                                               25700          11360          59           1         
  JUP JUP protein                                          100000         81675          90           3         
  apolipoprotein A-IV precursor                            42000          45371          2188         35        WB
  Inter-alpha-trypsin inhibitor heavy chain H2 precursor   200000         106370         1636         26        WB
  Pigment epithelium-derived factor precursor              50000          46313          529          11        
  Angiotensinogen precursor                                56300          53121          986          13        
  SERPINF2 protein                                         58000          55029          75           2         
  Actin, cytoplasmic 1                                     100000         41710          208          5         
  Thrombospondin-1 precursor                               175000         129300         152          4         
  Alpha-2-macro[g]{.ul}lobulin precursor                   180000         163175         559          18        
  -------------------------------------------------------- -------------- -------------- ------------ --------- ------------

^(1)^MOWSE score of candidate proteins.

^(2)^Number of peptide fragments yielding informative MS/MS data. The minimum significant threshold level of the probability-based MASCOT/MOWSE score was set at 5%.

^(3)^WB: western blot.

###### 

\(a\) Serum tumor marker levels in patients with pancreatic cancer.

  Gender     Age (years)     UICC-stage   Tumor size (mm)   CA19-9 (U/mL)   CEA (ng/mL)   ApoA-IV (AU)   GC (AU)     RBP4 (AU)
  ---------- --------------- ------------ ----------------- --------------- ------------- -------------- ----------- ------------
  M          38              IA           10                26.2            2.3           262.1          35.9        54.2
  M          50              IB           30                46.5            2.3           8.5            34.3        43.9
  M          63              IIA          18                157             1.1           10.2           26.7        37.0
  M\*        62              IIA          38                9               5             70.7           25.1        41.5
  M\*        54              IIA          24                11              1.4           87.5           11.3        42.5
  M          73              IIA          25                15.5            3.5           203.5          13.6        49.5
  F\*        76              IIA          26                13.3            1.5           70.7           33.1        43.2
  M          65              IIB          32                1579            3.4           352.1          24.3        36.7
  M\*        74              IIB          27                10.9            3.4           0              28.0        35.3
  F          74              IIB          40                43              3.2           54             25.8        38.9
  F          68              IIB          27                302             2.1           82.8           40.8        36.4
  M          61              IIB          30                10              1.4           134.7          27.3        46.2
  M          63              IIB          15                1080            ---           144.6          23.9        53.3
  M\*        73              IIB          50                13.9            2.1           23.2           1.8         43.1
  F          62              IIB          25                11.5            1.1           111.7          28.4        43.1
                                                                                                                     
  Ave ± SD   63.7 ± 1  0.4                27.8 ± 9.9        221.9 ± 466.2   63.7 ± 10.4   107.8 ± 99.9   25.4 ± 10   50.2 ± 4.2

CA19-9: carbohydrate antigen, CEA: carcinoembryonic antigen, ApoA-IV: apolipoprotein A-IV, GC: vitamin D-binding protein, RBP4: plasma retinol binding protein 4.

The stars indicate the patient who had a normal CA19-9 level and a low ApoA-IV.

Ave: average. SD: standard deviation. AU: arbitrary unit.

###### 

\(b\) Serum tumor marker levels in healthy controls.

  Gender     Age (years)   CA19-9 (u/mL)   CEA (ng/mL)   ApoA-IV (AU)   GC (AU)       RBP4 (AU)
  ---------- ------------- --------------- ------------- -------------- ------------- ------------
  M          71            33.9            2.2           157.4          29.5          47.7
  M          55            0.1             4.7           243.8          35.0          48.5
  M          55            6.4             1             223.0          35.3          54.3
  M          55            0.1             3.5           237.1          33.0          48.1
  M          60            7.7             0.8           237.1          23.9          44.1
  M          60            37.4            7             214.0          39.6          48.8
  M          61            7.6             4.8           277.0          16.8          49.7
  F          77            7.1             1.1           294.5          24.2          43.7
  M          61            7.8             1.3           80.6           33.4          55.3
  F          61            6               3             210.1          45.8          56.3
  F          65            2.9             2.1           65.7           61.7          53.3
  M          66            5.1             0.7           156.7          33.8          44.7
  F          62            11.7            1.7           122.9          33.0          50.9
  F          64            8.4             1.2           222.9          38.7          50.3
  F          71            24.4            2.6           184.7          30.5          56.3
                                                                                      
  Ave ± SD   62.9 ± 6.3    11.1 ± 11.5     2.5 ± 1.8     195.2 ± 66.9   34.3 ± 10.3   50.2 ± 4.2

CA19-9: carbohydrate antigen, CEA: carcinoembryonic antigen, ApoA-IV: apolipoprotein A-IV, GC: vitamin D-binding protien, RBP4: plasma retinol binding protein

Ave: average. SD: standard deviation. AU: arbitrary unit.

[^1]: Academic Editor: Tadashi Kondo
